Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial


White H. D. , Steg P. G. , Szarek M., Bhatt D. L. , Bittner V. A. , Diaz R., ...Daha Fazla

EUROPEAN HEART JOURNAL, cilt.40, sa.33, ss.2801-2809, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 40 Konu: 33
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1093/eurheartj/ehz299
  • Dergi Adı: EUROPEAN HEART JOURNAL
  • Sayfa Sayıları: ss.2801-2809

Özet

Aims The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin-kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (>= 1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI.